CD274 and osteosarcoma: One case study of a patient with pulmonary osteosarcoma metastases and high TMB treated with PD-L1 inhibitor therapy reported a durable response to treatment, with the patient experiencing a remission for at least two years despite discontinuation of treatment due to therapy related toxicities [196].